WDR43 and non-small cell lung carcinoma: Recently, TMB has gained significant momentum as a predictive indicator for pan-cancer through precision medicine.[33–35] TMB has the potential to be used as an indicator to increase the effectiveness of immunotherapy in NSCLC[36] and CRC.[37] Furthermore, MSI represents a significant indicator for immune checkpoint inhibitors.[38,39] According to our study, WDR43 expression is connected to MSI in 5 cancer forms, suggesting that the differential expression of WDR43 affects cancer MSI and can modulate the individual’s response to therapy involving immune checkpoint suppression.